MILFORD, Pa., Nov. 12, 2014 /PRNewswire/ -- Manzo
Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that Manzo's
Tummy Relief™ for babies is now being sold at Alitons Pharmacy
drug stores in New York and
Pennsylvania, and at The Medicine
Shoppe in Milford Pennsylvania. Kenneth Manzo, CEO,
stated that this is the beginning stage of promoting his product
and is seeking to have it sold by major chain
stores. Although Mr. Manzo already had a
relationship with Aliton's, he is also in talks with Walgreens and
others to have the product sold through their online properties as
well as their brick and mortar locations throughout the United States.
In addition, Manzo Pharmaceuticals today announced that they are
nearing the end of a six month animal study, which tests
Lacto-Freedom™, another of the company's products, and the results
of the lactase producing probiotic, looks like it'll come to a
close successfully. Successful results bring Manzo
Pharmaceuticals, and partner, Celprogen, Inc., one step closer to
human clinical trials, which will be part of the final preparations
for the product's release.
As stated previously, the 6-month study is being conducted by
Celprogen, Inc. using laboratory rats to test the new probiotic
treatment. Lab rats are the ideal mammals to test because they are
naturally lactose intolerant. After five months the rats given the
treatment showed no negative side effects, even at very high
doses. All doses from low to high concentration were very
successful at colonizing the intestines and producing lactase,
which enabled rats to digest lactose. This effect lasted for
a full five months after the administration of the
probiotic was discontinued. This long lasting
residual effect is unique and is far superior to any
other lactose intolerance treatment option currently on the
market. Since approximately 25% of the population in the United States is lactose intolerant Manzo
Pharmaceuticals and Celprogen are both confident that there
will be a huge demand for this product.
Both Manzo pharmaceuticals, and Celprogen are very pleased with
the results so far and eager to see the final result of how long
the effects last. It's possible that Lacto-Freedom™ could subdue
the symptoms of lactose intolerance for as much as the entire six
months or beyond. Because of that possibility, the partners are
beginning to seek out a company to do a human clinical trial.
The company has also recently convinced the DTCC to reopen the
"Chill" issue and is in the process of fulfilling the DTCC's
requests in order to lift the Chill that has been an obstacle in
gaining large volume and liquidity for several years. Mr. Manzo is
very confident that the DTC requirements will be met easily, and
the company will update the shareholders as soon as it has news
regarding its status. All efforts are being made to make Manzo
Pharmaceuticals a huge success.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, is a specialty pharmaceutical company
engaged in the research, development, and testing of patented and
non-patented solutions and remedies. Most notably is a patented
probiotic for people who suffer from Lactose Intolerance, and a
natural remedy for colic in babies. For more information follow the
company on twitter at @manzopharma, and visit:
www.manzopharma.com.
DISCLAIMER: This Press Release may contain certain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The Company has tried,
whenever possible, to identify these forward-looking statements
using words such as "anticipates," "believes," "estimates,"
"expects," "plans," "intends," "potential" and similar expressions.
These statements reflect the Company's current beliefs and are
based upon information currently available to it. Accordingly, such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance or achievements to differ materially
from those expressed in or implied by such statements. The Company
undertakes no obligation to update or advise in the event of any
change, addition or alteration to the information catered in this
Press Release including such forward-looking statements.
SOURCE Manzo Pharmaceuticals, Inc.